Respiratory Syncytial Virus Vaccine Protects Older Adults From Severe Disease

Respiratory syncytial virus prefusion F (RSVpreF) vaccine significantly reduced severe RSV-related lower respiratory tract disease (LRTD) requiring hospitalization or emergency department (ED) visits in an older adult population, including substantial representation from the oldest age groups.

Researchers performed a retrospective case-control study using data from a large US healthcare network to evaluate the effectiveness of the RSVpreF vaccine in protecting older adults against RSV-related hospitalization or ED visits.

The vaccine showed an estimated efficacy of 89% (95% CI, 13%-99%) against severe LRTD hospitalizations and ED events.

Source: MEDspace